Metoprolol tartrate is a Small Molecule owned by AstraZeneca, and is involved in 3 clinical trials, which were completed.
Metoprolol is a cardioselective competitive beta-1 adrenergic receptor antagonist with antihypertensive properties and devoid of intrinsic sympathomimetic activity. Metoprolol antagonizes beta 1-adrenergic receptors in the myocardium, thereby reducing the rate and force of myocardial contraction, and consequently a diminished cardiac output.
The revenue for Metoprolol tartrate is expected to reach a total of $1.7bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Metoprolol tartrate NPV Report.
Metoprolol tartrate Overview
Metoprolol Tartrate (Betaloc, Seloken, Beloken, Beloc) is an antiarrhythmic agent. It is formulated as injectable solution for intravenous route, tablet and hard gealtin capsules for oral route of administration. Metoprolol Tartrate is indicated in the treatment of for myocardial ischemia, tachycardia, post myocardial infraction, reduce cardiovascular risk factors, arrhythmias, essential hypertension, hypertension, angina pectoris prophylaxis, suspected or definite myocardial infarction, migraine prophylaxis, symptomatic treatment of hyperthyroidism and to treat disturbances of cardiac rhythm, in particular supraventricular tachyarrhythmias.
Recordati, a subsidiary of Fimei SpA, is a pharmaceutical company that researches, develops, manufactures and markets pharmaceuticals. The company offers pharmaceuticals for cardiovascular diseases, central nervous system disorders, dermatology, musculoskeletal disorders and analgesia, and urology diseases. It also offers cosmetics, dietary supplements, pregnancy test products, over-the-counter (OTC) and non-prescription pharmaceuticals, anti-infectives and others. It manufactures pharmaceutical chemicals such as active pharmaceutical ingredients (APIs) and intermediates. The company sells its pharmaceuticals directly in the countries of its operations and through licensees in other places. Recordati is headquartered in Milan, Italy.
The company reported revenues of (Euro) EUR1,580.1 million for the fiscal year ended December 2021 (FY2021), an increase of 9.1% over FY2020. In FY2021, the company’s operating margin was 31%, compared to an operating margin of 32.4% in FY2020. In FY2021, the company recorded a net margin of 24.4%, compared to a net margin of 24.5% in FY2020. The company reported revenues of EUR485.1 million for the third quarter ended September 2022, an increase of 2.5% over the previous quarter.
Quick View – Metoprolol tartrate
|Highest Development Stage|